6-mercaptopurine and azathioprine
Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with Allopurinol, a xanthine oxidase inhibitor, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels with consequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrently with allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If it is determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests t …
Identical in both labels. Surrounding text shown from Ipca Laboratories UK Ltd.
6 -Mercaptopurine and Azathioprine
Azathioprine is metabolised to 6-mercaptopurine, which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with allopurinol, a xanthine oxidase inhibitor, inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels with consequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrently with allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If it is determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests …
6-mercaptopurine and azathioprine
Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with allopurinol, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels withconsequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrentlywith allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If itis determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should bereduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologicmonitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising orbleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests th …
6-mercaptopurine and azathioprine: Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with Allopurinol, a xanthine oxidase inhibitor, inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels with consequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrently with allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If it is determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside): Evidence suggests th …
… ine is given concurrently with allopurinol, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity.
Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels withconsequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrentlywith allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If itis determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should bereduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologicmonitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising orbleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests th …
6-mercaptopurine and azathioprine
Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with allopurinol, a xanthine oxidase inhibitor, inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels with consequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrently with allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If it is determined that co-administration with 6- mercaptopurine or azathioprine is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests t …
6‑mercaptopurine and azathioprine
Azathioprine is metabolised to 6‑mercaptopurine which is inactivated by the action of xanthine oxidase. When 6‑mercaptopurine or azathioprine is given concurrently with Zyloric, a xanthine oxidase inhibitor, inhibition of xanthine oxidase will prolong their activity. Serum concentrations of 6-mercaptopurine or azathioprine may reach toxic levels with consequent life-threatening pancytopenia and myelosuppression when these medicinal products are given concurrently with allopurinol. Therefore, concomitant use of allopurinol with 6-mercaptopurine or azathioprine should be avoided. If it is determined that co-administration with 6-mercaptopurine or azathioprine is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests t …